Information Provided By:
Fly News Breaks for June 14, 2017
BIIB, ALXN
Jun 14, 2017 | 08:45 EDT
After Alexion (ALXN) named Biogen (BIIB) CFO Paul Clancy as its new CFO, Morgan Stanley analyst Matthew Harrison calls Clancy "a highly credible choice." Harrison thinks that the appointment of Clancy should ease investors' fears about the "stability" of the company's Soliris drug. The analyst adds that the CEO's forecast for "double digit growth," along with Clancy's appointment, should boost the stock today. He keeps a $138 price target and Overweight rating on the shares.
News For ALXN;BIIB From the Last 2 Days
BIIB
BIIB
BIIB
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.